Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
IRadimed Corporation is a U.S.-based medical device company that designs, manufactures, and markets MRI-compatible patient monitoring and intravenous (IV) infusion systems. The company operates within the medical devices and diagnostic imaging industries, with a specialized focus on equipment that can be safely used in the magnetic resonance imaging (MRI) environment. Its products are primarily used in hospitals and outpatient imaging centers to support patient safety and continuity of care during MRI procedures.
The company’s core revenue is driven by the sale of proprietary MRI-compatible IV infusion pumps, patient vital signs monitors, and related disposables and accessories. IRadimed is uniquely positioned as one of the few providers offering FDA-cleared infusion pump systems specifically designed for use in MRI suites, creating a niche competitive advantage supported by regulatory approvals and intellectual property. IRadimed was founded in 1992 and evolved from a development-stage company into a publicly traded medical device manufacturer, completing its initial public offering in 2014 and subsequently expanding its commercial footprint.
Business Operations
IRadimed operates as a single-reportable business focused on MRI-compatible medical devices, generating revenue primarily through product sales and recurring disposable components. Its flagship products include MRI-compatible IV infusion pump systems and patient monitoring systems that measure vital signs such as blood pressure, oxygen saturation, and ECG during MRI scans. These systems are designed to integrate into existing hospital workflows while meeting strict safety requirements for high magnetic field environments.
The company conducts manufacturing, product development, regulatory compliance, and commercial operations internally, with sales conducted through a combination of direct sales personnel and distribution partners. While the majority of revenue is generated in the United States, IRadimed also sells products internationally through third-party distributors. Based on available public disclosures, the company does not report material joint ventures, and Data inconclusive based on available public sources regarding the existence of significant operating subsidiaries beyond the parent entity.
Strategic Position & Investments
IRadimed’s strategic direction centers on expanding adoption of its MRI-compatible systems, increasing utilization through consumables, and extending its installed base within hospitals and imaging centers. Growth initiatives include product enhancements, incremental innovation to existing platforms, and expansion into new hospital departments that utilize MRI diagnostics. The company emphasizes regulatory compliance, clinical validation, and long product lifecycles as key strategic pillars.
Historically, IRadimed’s growth has been driven organically rather than through large acquisitions, and there is no verified public record of transformative mergers or acquisitions. Capital investments have focused on manufacturing capacity, research and development, and sales infrastructure. The company continues to monitor emerging imaging technologies and patient safety standards relevant to MRI environments, though Data inconclusive based on available public sources regarding material investments in adjacent or non-core technology sectors.
Geographic Footprint
IRadimed is headquartered in the United States, with its primary operations, manufacturing, and corporate functions based domestically. The U.S. market represents the company’s largest source of revenue, driven by widespread MRI utilization and established hospital purchasing channels.
Internationally, IRadimed maintains a presence across Europe, Asia-Pacific, and other select global markets through distributor relationships rather than direct subsidiaries. These international activities provide incremental revenue and brand visibility but are secondary to the company’s domestic operations. The company’s global reach is influenced by regulatory approvals in specific countries and the adoption of MRI safety standards across healthcare systems.
Leadership & Governance
IRadimed was founded by Larry Hornung, who played a central role in the early development of the company’s MRI-compatible technologies. The company is led by an executive team with experience in medical devices, healthcare technology, and public company governance, emphasizing disciplined growth, product reliability, and regulatory rigor.
Key executives include:
- Chris O. Scott – President and Chief Executive Officer
- Steven P. Cole – Chief Financial Officer
- William J. White – Chief Operating Officer
The leadership team’s strategic vision focuses on maintaining IRadimed’s niche leadership in MRI-compatible devices, leveraging long-term customer relationships, and sustaining profitability through innovation and operational efficiency.